[go: up one dir, main page]

FI971613L - Defektiivisiä adenoviruksia, jotka käsittävät terapeuttisen geenin ja immunoprotektiivisen geenin - Google Patents

Defektiivisiä adenoviruksia, jotka käsittävät terapeuttisen geenin ja immunoprotektiivisen geenin Download PDF

Info

Publication number
FI971613L
FI971613L FI971613A FI971613A FI971613L FI 971613 L FI971613 L FI 971613L FI 971613 A FI971613 A FI 971613A FI 971613 A FI971613 A FI 971613A FI 971613 L FI971613 L FI 971613L
Authority
FI
Finland
Prior art keywords
gene
immunoprotective
defective adenoviruses
therapeutic
therapeutic gene
Prior art date
Application number
FI971613A
Other languages
English (en)
Swedish (sv)
Other versions
FI971613A0 (fi
FI971613A7 (fi
Inventor
Martin Lee
Michel Perricaudet
Original Assignee
Rhone Poulenc Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Sa filed Critical Rhone Poulenc Sa
Publication of FI971613A0 publication Critical patent/FI971613A0/fi
Publication of FI971613A7 publication Critical patent/FI971613A7/fi
Publication of FI971613L publication Critical patent/FI971613L/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
FI971613A 1994-10-17 1995-10-11 Defektiivisiä adenoviruksia, jotka käsittävät terapeuttisen geenin ja immunoprotektiivisen geenin FI971613L (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9412346A FR2725726B1 (fr) 1994-10-17 1994-10-17 Vecteurs viraux et utilisation en therapie genique
PCT/FR1995/001326 WO1996012030A1 (fr) 1994-10-17 1995-10-11 Adenovirus defectifs comprenant un gene therapeutique et un gene immunoprotecteur

Publications (3)

Publication Number Publication Date
FI971613A0 FI971613A0 (fi) 1997-04-16
FI971613A7 FI971613A7 (fi) 1997-04-16
FI971613L true FI971613L (fi) 1997-04-16

Family

ID=9467911

Family Applications (1)

Application Number Title Priority Date Filing Date
FI971613A FI971613L (fi) 1994-10-17 1995-10-11 Defektiivisiä adenoviruksia, jotka käsittävät terapeuttisen geenin ja immunoprotektiivisen geenin

Country Status (11)

Country Link
US (1) US6669942B2 (fi)
EP (1) EP0787198A1 (fi)
JP (1) JP3816952B2 (fi)
AU (1) AU712243B2 (fi)
CA (1) CA2201399A1 (fi)
FI (1) FI971613L (fi)
FR (1) FR2725726B1 (fi)
IL (1) IL115584A (fi)
NO (1) NO971590D0 (fi)
WO (1) WO1996012030A1 (fi)
ZA (1) ZA958686B (fi)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2161095A1 (en) * 1993-04-20 1994-10-27 Solis Therapeutics, Inc. Methods and materials for treatment of individuals infected with intracellular infectious agents
US5872154A (en) * 1995-02-24 1999-02-16 The Trustees Of The University Of Pennsylvania Method of reducing an immune response to a recombinant adenovirus
US6251957B1 (en) 1995-02-24 2001-06-26 Trustees Of The University Of Pennsylvania Method of reducing an immune response to a recombinant virus
US6372208B1 (en) 1999-09-28 2002-04-16 The Trustees Of The University Of Pennsylvania Method of reducing an immune response to a recombinant virus
PT811073E (pt) * 1995-02-24 2007-03-30 Univ Pennsylvania Utilização de moduladores imunitários para preparar medicamentos que inibem as respostas imunitárias contra vírus recombinantes co-administrados
US6281010B1 (en) 1995-06-05 2001-08-28 The Trustees Of The University Of Pennsylvania Adenovirus gene therapy vehicle and cell line
US6783980B2 (en) * 1995-06-15 2004-08-31 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
KR100470180B1 (ko) 1995-06-15 2005-02-04 크루셀 홀란드 비.브이. 유전자 요법에 사용할 수 있는 인간의 재조합아데노바이러스 패키징 시스템
AUPN477695A0 (en) * 1995-08-14 1995-09-07 Commonwealth Scientific And Industrial Research Organisation Gene therapy
WO1998000166A1 (en) * 1996-07-03 1998-01-08 Merial, Inc. Recombinant canine adenovirus (cav) containing exogenous dna
WO1998010087A1 (en) * 1996-09-06 1998-03-12 Trustees Of The University Of Pennsylvania Chimpanzee adenovirus vectors
US6696423B1 (en) 1997-08-29 2004-02-24 Biogen, Inc. Methods and compositions for therapies using genes encoding secreted proteins such as interferon-beta
AU1288099A (en) 1997-10-30 1999-05-24 Cornell Research Foundation Inc. A method of inhibiting an immune response to a recombinant vector
US20030017138A1 (en) * 1998-07-08 2003-01-23 Menzo Havenga Chimeric adenoviruses
US20040043489A1 (en) * 1998-07-08 2004-03-04 Menzo Havenga Gene delivery vectors provided with a tissue tropism for dendritic cells and methods of use
US6929946B1 (en) * 1998-11-20 2005-08-16 Crucell Holland B.V. Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells
JP2002541815A (ja) * 1999-04-09 2002-12-10 シェーリング−プラウ・リミテッド ウシアデノウイルス１型から誘導された組換えアデノウイルスおよび変異アデノウイルス
US6451319B1 (en) 1999-04-09 2002-09-17 Schering-Plough Veterinary Corporation Recombinant and mutant adenoviruses
PT1816205E (pt) * 1999-05-17 2011-11-15 Crucell Holland Bv Adenovírus recombinante baseado no serótipo 48 (ad48)
US20050232900A1 (en) * 1999-05-18 2005-10-20 Crucell Holland B.V. Serotype of adenovirus and uses thereof
US6913922B1 (en) * 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
US6492169B1 (en) * 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
GB9924981D0 (en) 1999-10-21 1999-12-22 Univ Manchester Gene therapy
CN1254719A (zh) * 1999-11-19 2000-05-31 钱其军 一种缺陷型腺病毒及其构建方法
EP1157999A1 (en) * 2000-05-24 2001-11-28 Introgene B.V. Methods and means for enhancing skin transplantation using gene delivery vehicles having tropism for primary fibroblasts, as well as other uses thereof
CA2421864A1 (en) * 2000-09-20 2002-03-28 Crucell Holland B.V. Transduction of dendritic cells using adenoviral vectors
US7235233B2 (en) 2000-09-26 2007-06-26 Crucell Holland B.V. Serotype 5 adenoviral vectors with chimeric fibers for gene delivery in skeletal muscle cells or myoblasts
EP1203819A3 (en) * 2000-10-06 2002-08-07 Transgene S.A. Anti-inflammatory vectors
KR100432953B1 (ko) * 2001-09-01 2004-05-28 김주항 개선된 종양 살상 효과를 나타내는 재조합 아데노바이러스
ATE447037T1 (de) * 2002-04-25 2009-11-15 Crucell Holland Bv Mittel und verfahren zur herstellung von adenovirusvektoren
EP1786474B1 (en) 2004-08-12 2011-06-01 Cedars-Sinai Medical Center Combined gene therapy for the treatment of macroscopic gliomas
EP1856255A4 (en) 2005-02-11 2010-01-27 Univ Southern California PROCESS FOR EXPRESSING PROTEINS VIA DISULPHIDE BRIDGES
US20060286074A1 (en) * 2005-05-31 2006-12-21 Yucheng Tang Methods for immunotherapy of cancer
JP2009514536A (ja) * 2005-11-07 2009-04-09 シドニー キンメル キャンサー センター Ｃｄ４０リガンド融合蛋白質ワクチン
US8883493B2 (en) 2007-01-30 2014-11-11 Cedars-Sinai Medical Center Adenoviral vector comprising herpes simplex virus type 1 thymidine kinase and a transgene for increasing the expression of the transgene
US8802394B2 (en) 2008-11-13 2014-08-12 Radu O. Minea Method of expressing proteins with disulfide bridges with enhanced yields and activity
US10837020B2 (en) * 2009-04-22 2020-11-17 Massachusetts Institute Of Technology Innate immune suppression enables repeated delivery of long RNA molecules
EP2421563B1 (en) 2009-04-22 2017-04-12 Massachusetts Institute of Technology Innate immune suppression enables repeated delivery of long rna molecules
US20120237481A1 (en) * 2011-03-17 2012-09-20 Xiaoliu Zhang Incorporation of the B18R gene to enhance antitumor effect of virotherapy
US8445781B1 (en) 2011-11-15 2013-05-21 Nova D. Chasser Electrical receptacle cover having safety bracket for use with fragrance dispenser
AR109538A1 (es) 2016-09-20 2018-12-19 Boehringer Ingelheim Vetmedica Gmbh Vacuna contra la gripe porcina
WO2018054840A1 (en) 2016-09-20 2018-03-29 Boehringer Ingelheim Vetmedica Gmbh New promoters
BR112019005511A2 (pt) 2016-09-20 2019-10-01 Boehringer Ingelheim Vetmedica Gmbh vetores de adenovírus canino
EA201990711A1 (ru) 2016-09-20 2019-09-30 Бёрингер Ингельхайм Ветмедика Гмбх Новый ehv сайт инсерции orf70
US11839655B2 (en) 2017-09-01 2023-12-12 Microvax, Llc Combination cancer therapy
US20230321276A1 (en) 2020-09-30 2023-10-12 Alma Bio Therapeutics Nucleic acid therapy for differential modulation of host microflora

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69232890T2 (de) * 1991-10-04 2003-10-09 The Johns Hopkins University School Of Medicine, Baltimore Regulierung der systemischen immunantworten mittels zytokinen und antigenen
FR2688514A1 (fr) * 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
WO1994004196A1 (en) * 1992-08-14 1994-03-03 Imperial Cancer Research Technology Limited Tumour therapy
EP1024198A3 (en) * 1992-12-03 2002-05-29 Genzyme Corporation Pseudo-adenoviral vectors for the gene therapy of haemophiliae
FR2705686B1 (fr) * 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.

Also Published As

Publication number Publication date
NO971590L (no) 1997-04-07
IL115584A0 (en) 1996-01-19
FI971613A0 (fi) 1997-04-16
CA2201399A1 (fr) 1996-04-25
FR2725726B1 (fr) 1997-01-03
EP0787198A1 (fr) 1997-08-06
AU3658495A (en) 1996-05-06
JPH10507079A (ja) 1998-07-14
NO971590D0 (no) 1997-04-07
FI971613A7 (fi) 1997-04-16
FR2725726A1 (fr) 1996-04-19
JP3816952B2 (ja) 2006-08-30
WO1996012030A1 (fr) 1996-04-25
IL115584A (en) 2005-11-20
US6669942B2 (en) 2003-12-30
ZA958686B (en) 1996-05-22
AU712243B2 (en) 1999-11-04
US20020006395A1 (en) 2002-01-17

Similar Documents

Publication Publication Date Title
FI971613L (fi) Defektiivisiä adenoviruksia, jotka käsittävät terapeuttisen geenin ja immunoprotektiivisen geenin
DE69808753D1 (de) Mehrfachübertragungsvermittlung und -verfahren
FI971279A0 (fi) Lääkkeitä
GB2333161B (en) Electrode integrity checking
FI974494L (fi) Paikannusmenetelmä ja paikannusjärjestely
FI962927A7 (fi) Tetrasykliinijohdannaisia, valmistusmenetelmä ja käyttö
NO2008002I1 (no) Protiokonazol og salter derav
IS5425A (is) Læknislyf
FI980246A7 (fi) Menetelmä keittimen käyttämiseksi ja keitin
FI971747L (fi) Tietokone ja menetelmä tietokoneen käyttämiseksi
KR970702861A (ko) 포르포시아닌 및 cnc-확장된 포르피린(porphocyanine and cnc-expanded porphyrins)
BR9508339A (pt) Medicamento
NO20003268L (no) Hyperhydrert kitikolin, fremgangsmÕte og anvendelse
FI963164L (fi) Diabeteksen vastaisia peptidejä ja menetelmä
EE200000018A (et) 6-pürrolidiin-2-üülpüridiinid, nende valmistamine ja terapeutiline kasutamine
DE69430692D1 (de) Steckerstift
ITMI940559A0 (it) Innesto multiplo
FI965172A7 (fi) Uusia amido-kinoksaliinidioneja, niiden valmistus ja käyttö
DK48194A (da) Medicinsk elektrode
FI962725A7 (fi) Farmaseuttisia formulaatioita, jotka käsittävät polytioureaa sekä mene telmä niiden käyttämiseksi
FI20000980L (fi) Fysiologisesti hyväksyttäviä liuoksia ja menetelmiä niiden käyttämiseksi
ES1028196Y (es) Pins perfeccionado.
KR980004324U (ko) 의료용 가습기
NO944330D0 (no) Legemiddel
SE9401674L (sv) Läkemedel

Legal Events

Date Code Title Description
MA Patent expired